Q2 2026 saw revenues of $4.1B, with innovative brands up 43% YoY and generics down, leading to a net loss due to Emalex acquisition costs. 2026 guidance was raised for key brands, with improved gross margins and strong cash flow, despite ongoing risks and market pressures.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.